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Abstract
Backgroud: EBV-associated Gastric Carcinoma (EBVaGC) has a distinct clinical features and its prevalence is variable
worldwide.
Results: To determine the prevalence of EBVaGC in Tunisia, EBV-encoded small RNA (EBER) expression was
assessed in 81 gastric carcinoma (GC) specimens. The nuclear EBER expression was detected in 12 out of 81 GC
cases (14.81%) and concordance between the score range of EBER staining and the number of EBV DNA copies as
estimate by QPCR is observed. On the other hand, we found that EBVaGC strongly correlated with age at
diagnosis, and weakly with tumor differentiation and venous invasion.
Furthermore, the EBVaGC specimens were subjected to determine the EBV DNA polymorphisms. Our results show
a unique genetic profile of the EBV strains regarding the A and D types, the F prototype, the retention of XhoI
restriction site and the 30 bp del-LMP1 variant. According to our previous studies on nasopharyngeal carcinoma
(NPC), we suggested that EBV strains associated to GC and NPC shared some similarities in Tunisian patients.
Conclusion: The prevalence of EBVaGC is of 14.81% in the southern Tunisia and that common EBV strain are
associated with both NPC and GC which are likely to differ from Asian strains. Our findings support therefore a
certain geographical distribution of EBV strains which is not restricted to EBV-associated malignancies.
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Background
Gastric carcinoma (GC) is the second leading cause of
cancer death worldwide [1]. The incidence of GC varies
from one geographic region to another, suggesting that
genetic and environmental factors including Helicobac-
ter pylori infection are considered to contribute to gas-
tric carcinogenesis [2,3]. In southern Tunisia, the annual
incidence of GC varies from 2.6 to 4.8/100 000 persons
[4]. In the few past years, many reports have explored
the association between Epstein-Barr Virus (EBV) infec-
tion and GC [5-9]. The EBV-associated GC (EBVaGC)
has been evidenced by the presence of uniform expres-
sion of EBV-encoded small RNA (EBER) in GC cells
[10], the detection of monoclonal EBV episomes in GC
cells [11] and the increase of serum antibodies against
viral capsid antigen [12]. The incidence of EBVaGC var-
ies widely from 2 to 18% as reported by previous studies
[13-20]. Moreover, the clinical features of EBVaGC
include male predominance, relatively younger age and
location in the proximal stomach [9,21]. The EBVaGC
shows a lower rate of lymph-node involvement and has
a relatively favourable prognosis compared to EBV-nega-
tive one [22].
In EBVaGC, infection of tumor cells is characterized
by a type I pattern of latency, in which the expression of
viral latent genes is restricted to Epstein-Barr nuclear
antigen (EBNA)-1, EBER, latent membrane protein
LMP-2A and transcripts from the BamHI A rightward
frame (BARF)-0 and -1 [11,23]. Since the EBV products
of type I latent infection have been demonstrated to be
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gested that the oncogenic process in EBVaGC could be
driven by different mechanisms from those of conven-
tional GC. Subsequently, EBVaGC malignancy could be
considered as a different entity among GC which
requires greater attention to improve patient care.
The present study was conducted with the aim to
determine the prevalence of EBVaGC in southern Tuni-
sia and subsequently to analyze specific EBV poly-
morphisms in the tumor isolates.
Materials and methods
Patient’s characteristics
A total of 81 primary gastric carcinomas were collected,
between January 1999 and December 2009 from patients
who underwent radical surgical resection at the Depart-
ment of Digestive Surgery of Habib Bourguiba Univer-
sity Hospital (Sfax, Tunisia). All patients gave informed
consent prior to specimen collection according to insti-
tutional guidelines. None of the patients had pre-opera-
tive or post-operative chemotherapy. Clinico-
pathological parameters such as gender, age, anatomical
site, histological type, pathological stage, tumor size and
venous invasion were evaluated by reviewing medical
charts and pathological records. At the time of surgery,
the age of patients ranged from 18 to 94 years (mean:
59.58 years). The anatomical site of tumor was deter-
mined according to the predominant location of the
lesion as cardia (n = 8), body (n = 22), and antrum (n =
48). The histological subtypes were classified according
to the criteria of Lauren [24] as intestinal type (n = 47)
and diffuse type (n = 34) but also of World Health
Organization as poorly differentiated (n = 43), moder-
ately differentiated (n = 26) and well-differentiated (n =
9). The clinical stage of the disease was determined
according to the tumor, node and metastasis (TNM)
classification of the American Joint Committee on Can-
cer [25]. Our cohort contains 9 patients at stage I or II
and 47 patients at stage III or IV.
In-situ hybridization
EBV was identified by the expression of EBV-encoded
small RNA (EBER). Briefly, in situ hybridization (ISH)
assay was performed on 3 μm paraffin-block sections
with EBV oligonucleotide probes complementary to the
EBER-1 and -2 according to the manufacturer’s instruc-
tions (PNA ISH detection kit, Dako Cytomation). The
hybridization signals were visualized with diaminobenzi-
dine (DAB) and positive nuclear signal was recognized
as dark brown nuclear staining under light microscopy.
As positive control, section from a known EBER-positive
NPC tissue was used. Staining was scored from 1 to 3
according to the percentage of stained cell nuclei in tis-
sue sections. Score 3 was attributed when positive signal
w a so b s e r v e di nm o r et h a n7 5 % ,s c o r e2i n7 5t o5 0 %
and score 1 in less than 50% of cells.
DNA extraction
DNA was extracted from formalin-fixed, paraffin
embedded tissues. After tumor identification on hema-
toxylin-eosin-stained slides, tumoral areas were scraped
from 40 μm thick paraffin sections. The collected mate-
rials were de-waxed by washing in xylene and rinsed in
ethanol. Dried tissues were digested with proteinase K
in presence of SDS at 55°C overnight, followed by phe-
nol/chloroform extraction as described previously [26].
The quantity of DNA was checked by spectrophot-
ometer and stored at -20°C for further use.
PCR- RFLP and Sequencing
Five regions of the EBV genome were targeted for poly-
morphism analysis by PCR, RFLP or sequencing. The
polymorphisms studied encompass the A or B type in
the EBNA-3C gene, the C or D type in the BamHI-W1/
I1 region, the prototype F or f variant in the BamHI-F
region, the loss of an XhoIs i t ei nt h ef i r s te x o no f
BNLF1gene (XhoI-loss variant) and the 30 bp deletion
i nt h et h i r de x o no ft h es a m eg e n e( 3 0b pd e l - L M P 1
variant). Genotyping was performed on DNA from GC
patients EBV-positive and as control, we analyze 10
DNA samples from nasopharyngeal mucosa positive
for EBV.
PCR amplification was performed on 200 ng DNA in
a final reaction mixture of 50 μlc o n t a i n i n g0 . 2μMo f
each primer, 200 μMo fd N T P ,2m MM g C l 2 ,1 XP C R
buffer and 1 unit of Taq DNA polymerase (Fermentas).
The primer sequences and the size of PCR products are
shown in Table 1.
The C/D and F/f typing is based on the BamHI digestion
of each PCR product. The enzymatic reactions were carried
out in a final volume of 20 μl containing 10 μlo fP C Rp r o -
duct, 1X digestion buffer and 10 units of BamHI enzyme
(Fermentas). After overnight incubation at 37°C, products
were analyzed on 2% agarose gel and visualized by ethi-
dium bromide staining, under UV illumination. The same
c o n d i t i o n sd e s c r i b e da b o v ew e r ea s s e s s e dt oi d e n t i f yt h e
XhoI site in the first exon of BNLF1gene. DNA from B95.8
(GenBank accession No.V01555) and C666-1 cell line
(GenBank accession No. ABV54173) were used as control
for EBV types and variants. The C666-1 cell line derived
from a Chinese NPC that harbours A/C types, f variant,
XhoI-loss variant and 30 bp del-LMP1 variant.
DNA sequencing was performed on the purified PCR
products of the third exon of BNLF1 gene using the SV
gel Purification kit (Promega). Cycle sequencing was
performed using the ABI PRISM Big Dye Terminator
Cycle Sequencing Kit (Applied Biosystems) according to
the manufacturer’s instructions. All sequences were
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then compared with the EBV sequences of B95.8 (Gen-
Bank accession No.V01555), Chinese NPCs (Cao cells
[27], C666-1 cells (GenBank accession No. ABV54173)
and NPC10 biopsy [28] and Tunisian NPC specimens
(CV4, CV5, and CV6 [29]).
Real time quantitative PCR
Q-PCR assay targeting the BamHI-W region of the EBV
genome was performed on the 12 EBV-positive specimens
displaying nuclear staining and 6 EBV negative specimens.
Reactions were carried out on an iCycler iQ™ Real-time
PCR system (BioRad), using primers flanking the BamHI-
W region of the EBV genome and TaqMan probe as
described previously [30]. Aliquot of 1 μg DNA was used
for amplification in a total reaction volume of 25 μlc o n -
taining 300 nM of each primer, 25 nM of TaqMan probe,
1X PCR buffer, 2mM MgCl2, 200 μMo fe a c hd N T Pa n d
1 unit of GoTaq Hot Start polymerase (Promega). The
standard curve was prepared using serial 10-fold dilutions
of the recombinant plasmid pGEMT/BamHI-W. Samples
were run in duplicate and the results averaged to calculate
EBV viral load expressed in copies per reaction.
Statistical analysis
Statistical analysis was performed with SPSS 13.0 statis-
tical software program for Windows (SPSS Inc., Chi-
cago, Illinois, USA). P-value of less than 0.05 was
considered as statistically significant.
Results
Prevalence of EBVaGC and association with clinico-
pathological characteristics
Eighty one specimens of GC were tested for EBV posi-
tivity using the EBER in situ hybridization. The
frequency of EBVaGC was 14.8% (12 of 81) in which
the EBER positive signal was restricted to the nuclei of
carcinoma cells (Figure 1). The EBVaGC specimens
have a variable percentage of stained tumor cells
showing more than 75% in six cases (score 3), between
50 and 75% in three cases and less than 50% in the
three remaining cases. The EBVaGC cases were asso-
ciated with age at diagnosis (P = 0.009, Table 2). Indeed,
9o u to ft h e1 2p a t i e n t sw i t hE B V a G Cw e r ea g e d
between 45 to 60 years old. In addition, a trend toward
association was observed with tumor differentiation and
venous invasion as the statically significant value was
not reached (P =0 . 0 7a n dP=0.09 respectively, Table
2).
Quantitative assessment of EBV in GC
Q-PCR assay was performed on 18 gastric carcinoma
specimens; among them 12 displayed EBER positivity
restricted to cells nuclei and 6 were negative.
The viral DNA copy number was estimated by the
absolute quantification method using serial dilution of
recombinant plasmid DNA (pGEMT/BamHI-W), as
external standard. Standard curve was established by
plotting the starting plasmid copy number against the
threshold cycle (Ct), showing a linear quantification
over a range from 10
6 to 10 copies per reaction.
Representative examples are shown on Figure 2 where
c a s e sG C 1 0a n dG C 3( C t=1 5a n d2 2r e s p e c t i v e l y )d i s -
play strong EBER nuclear staining whereas GC8 (Ct =
30) exhibits a weak EBER expression (Figure 2). The Q-
PCR data is in concordance with EBER in situ hybridiza-
tion result. Indeed, the 6 specimens with intense EBER
staining (score 3+), showed high EBV DNA copy number
whereas cases with weak EBER expression (score 1+) cor-
responded to low viral DNA copy (Table 3).
Table 1 Summary of primer sequences encompassing the EBV types and variants
EBV genes and regions
(types or variants)
Primer sequences (5’-3’) Product size (bp)
EBNA-3C gene
(type A or B)
F: AGAAGGGGAGCGTGTGTTGT
R: GGCTCGTTTTTGACGTCGGC
PCR products
153: type A
246: type B
BamH1-W region
(type C or D)
F: ACCTGCTACTCTTCGGAAAC
R: TCTGTCACAACCTCACTGTC
PCR+ BamHI digestion
205: type C
130+75: type D
BamH1-F region
(f variant)
F: TCCCACCTGTTACCACATTC
R: GGCAATGGGACGTCTTGTAA
PCR+ BamHI digestion
198: F variant
127+71: f variant
Exon 1 of BNLF1 gene
(XhoI variant)
F: ACAATGCCTGTCCGTGCA
R: AGAAACACGCGTTACTCT
PCR+ XhoI digestion
497: XhoI-
340+157: XhoI+
Exon 3 of BNLF1 gene
(30bpdel-LMP1)
F: TGGAGGGAGAGTCAGTCAGGC
R: ATTGACGGAAGAGGTTGAAAAC
PCR products
224: 30bpdel-LMP1
254: wt-LMP1
F: Forward primer
R: Reverse primer
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Page 3 of 9Figure 1 Detection of Epstein-Barr virus encoded small RNAs (EBERs) by in-situ hybridization in gastric carcinoma tissues.A :H & E
staining. B: Intense EBER positive staining (immuno-score 3+) in the nuclei of tumor cells (original magnification × 40). C: Moderate EBER
positive staining (immuno-score 2+) in the nuclei of tumor cells (original magnification × 40). D: Weak EBER positive staining (immuno-
score 1+) in the nuclei of tumor cells (original magnification × 40). E: Positive control represented by a known EBER-positive NPC tissues
(original magnification × 40). F: Gastric carcinoma tissues negative for EBER (original magnification × 10).
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To further investigate the EBVaGC in our 12 Tunisian
specimens, we have examined the genetic profile of EBV
strains determining different types and variants. A
unique profile in all studied specimens is observed (Fig-
ure 3). It was characterized by the A/D types, prototype
F, retention of XhoI restriction site and 30 bp del-LMP1
variant. We note that the A and B types shaping two
different EBV strains were found in one case of
EBVaGC specimens (Figure 3).
The EBV DNA analysis was also performed by partial
sequencing on the third exon of the BNLF1 gene encod-
ing amino acids 328 to 376 of the LMP1 protein. In
order to confirm the 30 bp deletion encoding amino
acids 343 to 352 of the LMP1 protein, sequence align-
ment revealed seven amino-acids changes compared to
the reference strain B95.8. It was constantly found at
codons Q334R, L338S and S366A in all EBVaGC speci-
mens. The remaining amino acids substitutions, how-
ever, were especially found in one or two EBVaGC
specimens: H358L and L359V (GC2), P360H (GC9-10)
and G365R (GC6). Regarding our previous data on
Tunisian NPC specimens, we found similar results
about the three constant amino-acids substitutions. In
addition, the EBV strains harbouring S366A substitution
appear more associated to Tunisian specimens when
compared to those defined in China (Figure 4).
In healthy EBV carriers, polymorphism analysis
showed also the A and D types, prototype F and XhoI
+ variant, as similar to identify in EBVaGC speci-
mens (data not shown).
Discussion
In the present study, 81 cases of GC from patients of
the south region of Tunisia were investigated for the
presence of EBV and the prevalence of EBVaGC was
14.8% (12 out of 81). It was well known that the preva-
lence of EBVaGC varies widely from one geographical
region to another and the highest frequency was noted
in Germany (18%) whereas the lowest one (3.9%) was
detected in Peru [13-20,31].
The EBER in situ hybridization was the most reliable
method reported in the literature to detect latent EBV
in GC. In fact, all the above mentioned studies were
conducted following this method, including our study.
T h ev a r i a b l ep r o p o r t i o n so fn u c l e a rt u m o rc e l l st h a t
express EBER showing in our study were also deduced
by Truong et al., who suggest to be related with EBV
infection occurs in oncogenic process of EBVaGC [32].
However, further investigations must be conducted to
clarify this observation.
In addition, we showed that the heterogeneous data of
EBER expression could be correlated with the number
of EBV DNA copies as estimated by Q-PCR supporting
that this method is reliable as reported previously [33].
With regards to the clinico-pathological features of
EBVaGC, strong association with age at diagnosis was
observed (P = 0.009, Table 3). In fact, the EBVaGC was
more frequently found in the group of patients aged
between 45 and 60 years old, which is in line with pre-
vious studies [19,34]. No other statistical association was
Table 2 Correlation between EBVaGC and clinico-
pathological parameters
Clinical Characteristics N EBV expression*
Negative (%) Positive (%)
Gender
Male 48 42(87.5) 6 (12.5)
Female 33 27(81.8) 6 (18.2)
p-value 0.47
Age
< 45 17 17(100) 0(0)
45-60 30 21(70) 9(30)
> 60 34 31(91.2) 3(8.8)
p-value 0.009
TNM
I-II 9 9(100) 0(0)
III-IV 47 40(87.1) 7(14.9)
p-value 0.216
Anatomical site
Antrum 48 41(85.4) 7(14.6)
Body 22 19(86.4) 3 (13.6)
Cardia 8 6(75) 2(25)
p-value 0.72
Differentiation
Poor 43 36(83.7) 7 (16.3)
Moderate 26 25(96.2) 1 (3.8)
Well 9 6(66.7) 3(33.3)
p-value 0.075
Lauren type
Intestinal 47 38(80.9) 9(19.1)
Diffuse 34 31(91.2) 3(8.8)
p-value 0.197
Tumor size
< 5 cm 9 8(88.9) 1(11.1)
> 5 cm 65 54(83.1) 11(16.9)
p-value 0.658
Venous invasion
Negatif 61 54(88.5) 7(11.5)
Positif 18 13(72.2) 5(27.8)
p-value 0.09
* EBV expression was determined by EBER in-situ hybridization. Negative
cases exhibited a score = 0 and positives cases showed a score = 1+ to 3+.
BenAyed-Guerfali et al. Virology Journal 2011, 8:500
http://www.virologyj.com/content/8/1/500
Page 5 of 9found, except a tendency with tumor differentiation and
venous invasion (P =0 . 0 7 5a n dP = 0.09 respectively).
Previous reports have indicated that EBVaGC were
frequent in male, proximal stomach and tumors of
diffuse type [9,14,16,35-39].Recently, in a large meta-
analyse, Carmago et al., confirms these associations
in addition to the age at diagnosis [38]. In our study,
we didn’t find difference in the distribution of EBV in
male compared to female patients, in proximal vs
distal stomach and in diffuse vs intestinal histotype.
These variations between data could be explained by
the contribution of local risk factors in the pathogen-
esis of EBV and also by the size and charasteristics of
the cohort.
Polymorphism analysis of the 12 EBVaGC cases show
exclusively the type D, prototype F, XhoI-retention and
the 30 bp del-LMP1 variant. Concerning the poly-
morphism of the EBNA-3C gene, we found the A type
in all EBVaGC cases and a combination of types A and
B was found in only one case. These findings are in
agreement with recent study conducted on four
EBVaGC cases from the central region of Tunisia [34].
The predominance of type A and prototype F was also
s h o w ni np r e v i o u sr e p o r t si n d e p e n d e n t l yt ot h eg e o -
graphic origin of EBVaGC as in southern China [35],
southern Japan [40], and Latin American countries [41].
Figure 2 Determination of EBV DNA copy number by Q-PCR. Representative examples of GC cases with high (GC10), intermediate (GC3) and
low (GC8) EBV DNA copies number. The horizontal line marks the threshold used for assessment of Ct value.
Table 3 EBV DNA copy number and EBER staining score
in the 12 EBV positive specimens and 6 negative cases
GC
Cases
Histological
Type
Tumor
Site
Ct*
(average)
EBV DNA*
Copies/μg
EBER
staining
score
10 Intestinal Antrum 15 6.10
5 3+
3 Intestinal Antrum 22 4.10
3 3+
12 Intestinal Antrum 23 10
3 3+
9 Diffuse Antrum 22.8 10
3 3+
2 Intestinal Body 25 5.10
2 3+
4 Intestinal Antrum 26 10
2 3+
6 Intestinal Proximal 27 8.10
1 2+
7 Diffuse Body 28 5.10
1 2+
11 Intestinal Proximal 28 5.10
1 2+
1 Intestinal Antrum 30 < 10 1+
5 Intestinal Antrum 30 < 10 1+
8 Diffuse Body 30 < 10 1+
13 Diffuse Antrum ND ND 0
14 Diffuse Body ND ND 0
15 Diffuse Antrum ND ND 0
16 Diffuse Antrum ND ND 0
17 Intestinal Antrum ND ND 0
18 Intestinal Body ND ND 0
* EBV DNA copy number was estimated by Q-PCR using the absolute
quantification method. Ct: threshold Cycle. ND: Non-Determined
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NPC associated EBV strains of southern Asia [42]. In
this area, a predominance of C type and loss-XhoI var-
iant was observed in patients with EBVaGC or NPC
[35,40], in contrast to our present finding and previous
data on Tunisian NPC patients [29,43].
To better define the genotype of EBVaGC strains
and compare them with those associated with the
Figure 3 Genotyping of EBVaGC strains. A: PCR -RFLP of the BamHI-F region showing the f variant (presence of two bands of 128 bp and 71
bp) for the control C666-1 cell line (lane 1) and one band of 199 bp for the F variant for cases GC2 to GC6 (lane 2 to 6). B: PCR-RFLP of the
BamHI-W1/I1 region. DNA fragments were digested with BamHI giving two bands of 139 and 67 bp (type D) for GC2 to GC6 (lane 2 to 6) or
one band of 245 bp (type C) for the control C666-1 cell line (lane 1). C: EBNA3C region. EBV strains of types A and B correspond to DNA
fragment of 153 and 246 bp respectively. Case GC6 shows dual infection with both types A and B viruses. B95.8 is a type A virus that was used
as a control (lane 1). D: XhoI polymorphism in exon 1 of the BNLF1 gene. PCR product was digested by XhoI to yield two bands of 343 bp and
154 bp in XhoI+ variant for GC2 to GC6 (lane 2 to 6). C666-1 cell line is a positive of loss-XhoI variant (lane 1).
Figure 4 Comparison of deduced amino acid sequences from Tunisian GC with B95.8 prototype and previously published LMP1
sequences: Cao: NPC cell line from Shangai [27]; C666-1 (GenBank accession No. ABV54173) NPC 10 from Hong Kong [28]and Tunisian
NPC specimens: CV4, CV5, CV6 [29]. Symbols (—) indicate amino acid deletion.
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of the BNLF1 gene and compared them to the proto-
type B95-8 and others published sequences from Asian
and Tunisian NPC EBV strains [29,43]. The Q334R,
L338S and L338P were found in all our EBV isolates
and were already reported in EBV strains associated to
NPC originating from China or Tunisia [29,44]. How-
ever, the S366A is specific to EBV isolates associated
with Tunisian NPC and GC.. Indeed, and based on the
previous report of Edwards et al., [44]describing seven
phylogenetically distinct strains of LMP1, we can pro-
pose that Tunisian isolates constitute a supplemen-
tary group with a specific signature (T366A) but this
hypothesis needs confirmation by sequencing of the
entire BNLF1 gene in these isolates. According to this
date, we suggest that polymorphism in the BNLF1
gene constitute an additional argument in line with
t h eo t h e r sE B Vp o l y m o r p h i s m s( Dt y p e ,p r o t o t y p eF
and XhoI+) supporting the dissimilarity of EBV
strains between the two geographic regions.
On the other hand, we have described previously others
del-LMP1 variants (69 bp and 81 bp deletion spanning
codons 334-353 and 345-371, respectively) in Tunisian
NPC patients [29,43]. These variants were not found and
only the 30 bp del-LMP1 variant was identified in all
EBVaGC cases as already reported by Chen et al., in a
large study conducted on Chinese GC patients [35].
Our polymorphism analysis of EBV isolates in
healthy carriers revealed an identical genotype to
t h o s eo fE B V a G Ca n dN P Cs u g g e s t i n gt h a tc o m m o n
strains are geographically distributed but not asso-
ciated with a specific malignancy. In fact, the devel-
opment of EBV associated malignancies could be
correlated to variation in potential immune recogni-
tion in distinct populations and individuals, as pro-
posed by Edwards et al, [44].
Conclusion
The prevalence of EBVaGC in patients from southern
Tunisia is 14.8% which is in range with reported data.
The EBVaGC was predominantly found in the group of
patients aged from 45 to 60 years old and that EBV
DNA level reflect the EBER status in gastric carcinoma.
Furthermore, EBV strains associated to Tunisian
patients with GC or NPC share some similarities sug-
gesting that probably the same EBV strain are associated
with both tumors. Altogether, our findings support the
different geographical distribution of EBV strains, but
not their restriction to an associated malignancy.
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